iSpecimen Inc. Proceeds from (Repayments of) Long-term Debt and Capital Securities
iSpecimen Inc. (ISPC) reported Proceeds from (Repayments of) Long-term Debt and Capital Securities of -$3.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities · last filed 2024-03-13
- iSpecimen Inc. proceeds from (repayments of) long-term debt and capital securities for fiscal 2022 was -$3.50M.
| Period end | Proceeds from (Repayments of) Long-term Debt and Capital Securities 12 month |
|---|---|
| 2022-12-31 | -$3.50M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |